[an error occurred while processing this directive] | [an error occurred while processing this directive]
Precision thoracic radiotherapy in limited-stage small cell lung cancer:a network meta-analysis
Yang Tao1, Cao Lijuan2, Jiang Xiaodong1, Fan Yuwei1, Li Jia1, Wu Dan1, Chen Hanbo1, Xia Youyou1
1Department of Radiation Oncology, the First People's Hospital of Lianyungang City, Lianyungang 222002, China; 2Department of Healthcare-associated Infection Management, the First People's Hospital of Lianyungang City, Lianyungang 222002, China
AbstractObjective To systematically evaluate the efficacy and safety of precision thoracic radiotherapy (TRT) in the limited-stage small cell lung cancer (LS-SCLC) patients by network meta-analysis. Methods Randomized controlled trials (RCTs) of TRT regimes in the LS-SCLC were electronically searched from PubMed, Web of Science, The Cochrane Library, CNKI and Wanfang Data from inception to September 1st, 2021. Two reviewers independently screened literature, extracted data and assessed the risk of bias of included studies. Statistical analysis was performed by Stata 17 and R 4.1.1software. Results A total of 6 RCTs involving 1730 patients with six radiation regimens including hyperfractionated radiotherapy (HFRT):HFRT45(45Gy/30 F) and HFRT60(60Gy/40 F);conventional fractionated radiotherapy (CFRT):CFRT70(70Gy/35 F) and CFRT66(66Gy/33 F);moderately hypofractionated radiotherapy (MHFRT):MHFRT65(65Gy/26 F) and MHFRT42(42Gy/15 F) were included. The network meta-analysis showed that:in terms of improving progression-free survival and overall survival, there was no statistically significant difference among the six radiotherapy regimens. The probabilistic ranking results were:MHFRT65 > HFRT60 > CFRT66 > CFRT70 > MHFRT42 > HFRT45, and HFRT60 > MHFRT65 > CFRT66 > CFRT70 > HFRT45 > MHFRT42, respectively. The HFRT60 regimen was superior to other regimens in reducing the incidence of grade ≥3 pneumonia, and there was no difference between the regimens in causing grade ≥3 radiation esophagitis, and the results of ranking probability were:HFRT60 > MHFRT42 > CFRT66 > CFRT70 > HFRT45 > MHFRT65, and HFRT60 > CFRT70 > CFRT66 > HFRT45 > MHFRT42 > MHFRT65, respectively. Conclusions HFRT60 radiotherapy regimen may be more effective and safer in the treatment of LS-SCLC patients as a priority choice for LS-SCLC TRT. Limited by the number and quality of included studies, the above conclusions need to be verified by more high-quality studies.
Yang Tao,Cao Lijuan,Jiang Xiaodong et al. Precision thoracic radiotherapy in limited-stage small cell lung cancer:a network meta-analysis[J]. Chinese Journal of Radiation Oncology, 2022, 31(5): 431-437.
Yang Tao,Cao Lijuan,Jiang Xiaodong et al. Precision thoracic radiotherapy in limited-stage small cell lung cancer:a network meta-analysis[J]. Chinese Journal of Radiation Oncology, 2022, 31(5): 431-437.
[1] Howlader N, Forjaz G, Mooradian MJ, et al. The effect of advances in lung-cancer treatment on population mortality[J]. N Engl J Med, 2020, 383(7):640-649. DOI:10.1056/NEJMoa1916623. [2] Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021[J]. CA Cancer J Clin, 2021, 71(1):7-33. DOI:10.3322/caac.21654. [3] 中华医学会放射肿瘤治疗学分会, 中国医师协会放射肿瘤治疗医师分会, 中国抗癌协会放射治疗专业委员会, 等. 中国小细胞肺癌放射治疗临床指南(2020版)[J]. 中华放射肿瘤学杂志, 2020, 29(8):608-614. DOI:10.3760/cma.j.cn113030-20200528-00285. Clinical practice guideline for radiation therapy in small cell lung cancer (2020 version)[J]. Chinese Journal of Radiation Oncology,2020,29(8):608-614. DOI:10.3760/cma.j.cn113030-20200528-00285. [4] Nicholson AG, Chansky K, Crowley J, et al. The international association for the study of lung cancer lung cancer staging project:proposals for the revision of the clinical and pathologic staging of small cell lung cancer in the forthcoming eighth edition of the TNM classification for lung cancer[J]. J Thorac Oncol, 2016, 11(3):300-311. DOI:10.1016/j.jtho.2015.10.008. [5] 中国临床肿瘤学会指南工作委员会. 小细胞肺癌诊疗指南(2020版)[M]. 北京:人民卫生出版社,2020. Chinese Society of Clinical Oncology Guidelines Committee. Clinical Practice Guidelines for diagnosis treatment and follow-up in small cell lung cancer (2020 version)[M]. Beijing:People's Medical Publishing House,2020. [6] Colaco R, Sheikh H, Lorigan P, et al. Omitting elective nodal irradiation during thoracic irradiation in limited-stage small cell lung cancer—evidence from a phase Ⅱ trial[J]. Lung Cancer, 2012, 76(1):72-77. DOI:10.1016/j.lungcan.2011.09.015. [7] Grønberg BH, Halvorsen TO, FløttenØn,et al. Randomized phase Ⅱ trial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer[J]. Acta Oncol, 2016, 55(5):591-597. DOI:10.3109/0284186X.2015.1092584. [8] Faivre-Finn C, Snee M, Ashcroft L, et al. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT):an open-label, phase 3, randomised, superiority trial[J]. Lancet Oncol, 2017, 18(8):1116-1125. DOI:10.1016/S1470-2045(17)30318-2. [9] Grønberg BH, Killingberg KT,FløttenØn,et al. High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer:an open-label, randomised, phase 2 trial[J]. Lancet Oncol, 2021, 22(3):321-331. DOI:10.1016/S1470-2045(20)30742-7. [10] Qiu B, Li Q, Liu J, et al. Moderately hypofractionated once-daily compared with twice-daily thoracic radiation therapy concurrently with etoposide and cisplatin in limited-stage small cell lung cancer:A multicenter, phase Ⅱ, randomized trial[J]. Int J Radiat Oncol Biol Phys, 2021, 111(2):424-435. DOI:10.1016/j.ijrobp.2021.05.003. [11] Jeffrey AB, Wang XF, Gregory AM, et al. Phase 3 comparison of high-dose once-daily (QD) thoracic radiotherapy (TRT) with standard twice-daily (BID) TRT in limited stage small cell lung cancer (LSCLC):CALGB 30610(Alliance)/RTOG 0538[J]. J Clin Oncol,2021,39(suppl 15):8505. [12] De Ruysscher D, Lueza B, Le Péchoux C, et al. Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer:usefulness of the individual patient data meta-analysis[J]. Ann Oncol, 2016, 27(10):1818-1828. DOI:10.1093/annonc/mdw263. [13] Turrisi AT 3rd, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide[J]. N Engl J Med, 1999, 340(4):265-271. DOI:10.1056/NEJM199901283400403. [14] Xia B, Hong LZ, Cai XW, et al. Phase 2study of accelerated hypofractionated thoracic radiation therapy and concurrent chemotherapy in patients with limited-stage small-cell lung cancer[J]. Int J Radiat Oncol Biol Phys, 2015, 91(3):517-523. DOI:10.1016/j.ijrobp.2014.09.042. [15] Wang K, Tepper JE. Radiation therapy-associated toxicity:etiology, management, and prevention[J]. CA Cancer J Clin, 2021, 71(5):437-454. DOI:10.3322/caac.21689. [16] Farrell MJ, Yahya JB, Degnin C, et al. Radiation dose and fractionation for limited-stage small-cell lung cancer:survey of US radiation oncologists on practice patterns[J]. Clin Lung Cancer, 2019, 20(1):13-19. DOI:10.1016/j.cllc.2018.08.015.
2022, Vol. 31 
